Вирус папилломы человека – новый этиологический фактор в развитии рака органов головы и шеи. Проблемы и перспективы их решения
Аннотация
Плоскоклеточный рак органов головы и шеи занимает 5-е место в структуре онкологической заболеваемости в мире. Смертность от этой патологии не меняется на протяжении уже нескольких десятилетий, несмотря на значительные успехи и достижения в современной клинической онкологии. В статье детально рассмотрены и проанализированы: этиологическая роль в развитии рака ротоглотки вируса папилломы человека (ВПЧ); половые и возрастные особенности ВПЧ-ассоциированного рака, различные методы предиктовой диагностики, специфическая профилактика. Сделаны выводы: папилломавирусная инфекция является основной причиной резкого и продолжающегося роста заболеваемости раком ротоглотки в основном среди мужчин во многих странах мира; вакцинация несет позитивные ожидания в профилактике заболеваемости раком ротоглотки.
Об авторе
А. М. Мудунов
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Россия
Али Мурадович Мудунов – доктор медицинских наук, профессор, руководитель отдела опухолей головы и шеи.
МоскваСписок литературы
1. Gupta S, Kong W, Peng Y, Miao Q, Mackillop WJ. Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int. J. Cancer 2009; 125: 2159–2165.
2. Mehanna H, Beech T, Nicholson T, et al: The prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer: Systematic review and meta-analysis of trends by time and region. Head Neck. 2013; 35: 747–755,
3. The Nobel Prize in Physiology or Medicine 2008 [press release] Stockholm, Sweden: The Nobel Assembly at Karolinska Institutet; 2008. Oct 6, [Accessed November 20, 2009]. Aviable at: http://nobelprize.org/nobel_prizes/medicine/laureates/2008/press.html.
4. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92 (9): 709–720.
5. International Agency for Research on Cancer (ed): IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, in Human Papillomaviruses. Lyon, France, World Health Organization. 2007: 670.
6. Anil K. Chaturvedi, Eric A. Engels et al. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. JCO. 10. 2011: 4294–4301.
7. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. .Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma. JCO. 2015: 3235–3242.
8. US Department of Health and Human Services: Trends in Hospital Utilization: United States, 1965-1986, in National Center for Health Statistics. Hyattsville, MD, Department of Health and Human Services Publication, 1989.
9. Fakhry C, Andersen K, Christensen J, et al: The impact of tonsillectomy upon the risk of oropharyngeal carcinoma diagnosis and prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) [epub ahead of print on April 20, 2015].
10. Jemal A, Simard EP, Dorell C, et al: Annual report to the nation on the status of cancer, 1975- 2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013; 105: 175–201.
11. Giuliano AR, Nyitray AG, Kreimer AR, et al: EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015; 136: 2752–2760,
12. Ho GY, Studentsov Y, Hall CB, et al: Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002; 186: 737–742.
13. Chaturvedi AK, Engels EA, Anderson WF, et al: Incidence trends for human papillomavirus- related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26: 612–619.
14. Jit M, Brisson M, Portnoy A, et al: Cost- effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study. Lancet Glob Health. 2014; 2: e406–e414.
15. International Agency for Research on Cancer (ed): Primary end-points for prophylactic HPV vaccine trials, in IARC Working Group Reports. Geneva, Switzerland, World Health Organization. 2014: 1–104.
16. Herrero R, Quint W, Hildesheim A, et al: Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013; 8: e68329.
17. Gillison ML, Alemany L, Snijders PJ, et al: Human papillomavirus and diseases of the upper airway: Head and neck cancer and respiratory papillomatosis. Vaccine. 2012 (suppl 5) 30: F34–F54.
18. Ahn SM, Chan JY, Zhang Z, et al: Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014; 140: 846–854.
19. Kreimer AR, Johansson M, Waterboer T, et al: Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013; 31: 2708–2715.
20. Catherine de Martel et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017; 141: 664–670.
21. Das LC, Karrison TG, Witt ME, et al. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015; 26 (1): 198–205.
22. Cmelak A, Li S, Marur S, et al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). J Clin Oncol. 2014; 32 (5s): abstr LBA6006.
23. Everett E. Vokes, Nishant Agrawal, Tanguy Y. Seiwert. HPV-Associated Head and Neck Cancer. JNCI J Natl Cancer Inst. 2015; 107 (12): 1–7.
24. Carole Fakhry and Maura L.Gillison. Clinical Implications of Human Papillomavirus in Head and Neck Cancers. J Clin Oncol. 2006; 24 (17): 2606–2611.
25. K. Kian Ang et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med. 2010; 363: 24–35.
26. Tara A. Berman et al. Human Papillomavirus in Cervical Cancer and Oropharyngeal Cancer: One Cause, Two Diseases. Cancer. 2017: 2219–2229.
27. Matthew H. Stenmark, et al. Nonendemic HPV-Positive Nasopharyngeal Carcinoma: Association With Poor Prognosis. Int J Radiation Oncol Biol Phys. 2014; 88 (3): 580–588.
Для цитирования:
Мудунов А.М. Вирус папилломы человека – новый этиологический фактор в развитии рака органов головы и шеи. Проблемы и перспективы их решения. Эпидемиология и Вакцинопрофилактика. 2018;17(5):100-105. https://doi.org/10.31631/2073-3046-2018-17-5-100-105
For citation:
Mudunov A.M. The Human Papilloma Virus is a New Etiologic Factor in the Development of Cancer of the Head and Neck Organs. Problems and Prospects for their Solution. Epidemiology and Vaccinal Prevention. 2018;17(5):100-105. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-5-100-105
Просмотров: 606
Послать статью по эл. почте 